Evolus
Performance beauty company providing medical aesthetic products (botulinum toxin and dermal fillers) to physicians and patients in the cash-pay aesthetics market.
- CEO / Founder
- David Moatazedi
- Team Size
- 201-500
- Stage
- Public
- Total Funding
- $150M
- Latest Round
- IPO
Technology & Products
Key Products
Jeuveau (botulinum toxin type A); Evolysse (hyaluronic acid dermal fillers); Estyme (dermal filler)
Technological Advantage
Evolus's core product, Jeuveau, is a botulinum toxin type A approved by the FDA in 2019. The company's advantage lies in its licensing agreement with Daewoong Pharmaceutical (2013) and its commercial execution in the aesthetics market. The IP is licensed, not proprietary, making it replicable by competitors.
Differentiation
Value Proposition
Provides FDA-approved aesthetic injectables (Jeuveau, Evolysse) with a customer-centric approach, offering expanded choices in the cash-pay aesthetics market.
How They Differentiate
Evolus competes in the aesthetic botulinum toxin market with a focus on the cash-pay segment, offering a more affordable alternative to Botox. Its differentiation is primarily commercial (pricing, customer engagement) rather than technological.
Market & Competition
Target Customers
Physicians, clinics, and medical aesthetic practices
Industry Verticals
Medical Aesthetics; Pharmaceuticals
Competitors
AbbVie (Botox); Galderma; Merz Pharma; Revance Therapeutics
Growth & Milestones
Growth Metrics
Q2 2026 net revenue of $84.1M, up 21% YoY; Q1 2026 revenue of $73.1M, up 7% YoY; FY2025 revenue guidance between $295M and $305M; third consecutive quarter of positive adjusted EBITDA in Q2 2026.
Major Milestones
Founded in 2012; IPO on February 8, 2018; FDA approval of Jeuveau in 2019; Fifth anniversary of Jeuveau launch in 2024; National launch of Evolysse filler line
Notable Customers
Physicians and medical aesthetic practices in the US and internationally